CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma

Cancer Medicine

Volumn 5, Issue 3, 2016, Pages 398-406

  Cuccaro, Annarosa ^a   Annunziata, Salvatore ^a   Cupelli, Elisa ^a   Martini, Maurizio ^a   Calcagni, Maria L ^a   Rufini, Vittoria ^a   Giachelia, Manuela ^a   Bartolomei, Francesca ^a   Galli, Eugenio ^a   D'Alò, Francesco ^a   Voso, Maria t ^a,b   Leone, Giuseppe ^a   Giordano, Alessandro ^a   Larocca, Luigi M ^a   Hohaus, Stefan ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

CD68+ tumor infiltrating macrophages; Hodgkin lymphoma; Interim PET; Prognosis; TARC

Indexed keywords

BLEOMYCIN; CD68 ANTIGEN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VINBLASTINE; ANTINEOPLASTIC AGENT; CCL17 PROTEIN, HUMAN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADOLESCENT; AGE DISTRIBUTION; AGED; ARTICLE; B SYMPTOM; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW RISK POPULATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREND STUDY; ADULT; B LYMPHOCYTE SUBPOPULATION; BLOOD; CYTOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTE SUBSETS; CELL COUNT; CHEMOKINE CCL17; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85006224556     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.585     Document Type: Article

References (38)

1. Townsend, W., and D. Linch . 2012. Hodgkin's lymphoma in adults. Lancet 380:836-847.
2. Advani, R. 2011. Optimal therapy of advanced Hodgkin lymphoma. Hematology 2011:310-316.
3. Diehl, V., J. Franklin, M. Pfreundschuh, B. Lathan, U. Paulus, D. Hasenclever, et al. 2003. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348: 2386-2395.
4. Engert, A., V. Diehl, J. Franklin, A. Lohri, B. Dörken, W. D. Ludwig, et al. 2009. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 27:4548-4554.
5. Wongso, D., M. Fuchs, A. Plütschow, B. Klimm, S. Sasse, B. Hertenstein, et al. 2013. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin study group. J. Clin. Oncol. 31:2819-2824.
6. Eichenauer, D. A., I. Thielen, H. Haverkamp, J. Franklin, K. Behringer, T. Halbsguth, et al. 2014. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 123:1658-1664.
7. Behringer, K., H. Mueller, H. Goergen, I. Thielen, A. D. Eibl, V. Stumpf, et al. 2013. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J. Clin. Oncol. 31:231-239.
8. Venkataraman, G., M. K. Mirza, D. A. Eichenauer, and V. Diehl . 2014. Current status of prognostication in classical Hodgkin lymphoma. Br. J. Haematol. 165:287-299.
9. Cuccaro, A., F. Bartolomei, E. Cupelli, E. Galli, M. Giachelia, and S. Hohaus . 2014. Prognostic factors in Hodgkin lymphoma. Mediterr. J. Hematol. Infect. Dis. 6:e2014053. doi: 10.4084/MJHID.2014.053. eCollection 2014.
10. Gallamini, A., L. Rigacci, F. Merli, L. Nassi, A. Bosi, I. Capodanno, et al. 2006. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475-481.
11. Hutchings, M., A. Loft, M. Hansen, L. M. Pedersen, A. K. Berthelsen, S. Keiding, et al. 2006. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482-489.
12. Gallamini, A., M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, et al. 2007. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25:3746-3752.
13. Gallamini, A., S. F. Barrington, A. Biggi, et al. 2014. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107-1113.
14. Avigdor, A., S. Bulvik, I. Levi, et al. 2010. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann. Oncol. 21:126-132.
15. Dann, E. J., Z. Blumenfeld, R. Bar-Shalom, et al. 2012. A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am. J. Hematol. 87:32-36.
16. Meignan, M., A. Gallamini, and C. Haioun . 2009. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk. Lymphoma 50:1257-1260.
17. Barrington, S. F., N. G. Mikhaeel, L. Kostakoglu, et al. 2014. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J. Clin. Oncol. 32: 3048-3058.
18. Gallamini, A., C. Patti, S. Viviani, et al. 2011. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br. J. Haematol. 152:551-560.
19. Rossi, C., S. Kanoun, A. Berriolo-Riedinger, et al. 2014. Interim 18F-FDG PET SUV max reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J. Nucl. Med. 55:569-573.
20. Moskowitz, C. H., M. J. Matasar, A. D. Zelenetz, et al. 2012. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665-1670.
21. Steidl, C., T. Lee, S. P. Shah, et al. 2010. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362:875-885.
22. Hohaus, S., R. Santangelo, M. Giachelia, et al. 2011. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin. Cancer Res. 17:2885-2892.
23. Kamper, P., K. Bendix, S. Hamilton-Dutoit, et al. 2011. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 96:269-276.
24. Azambuja, D., Y. Natkunam, I. Biasoli, et al. 2012. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann. Oncol. 23:736-742.
25. Tan, K. L., D. W. Scott, F. Hong, et al. 2012. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120:3280-3287.
26. Sánchez-Espiridión, B., A. M. Martin-Moreno, C. Montalbán, et al. 2012. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 97:1080-1084.
27. Greaves, P., A. Clear, R. Coutinho, et al. 2013. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J. Clin. Oncol. 31:256-262.
28. Touati, M., M. Delage-Corre, J. Monteil, et al. 2015. CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk. Lymphoma 56:332-341.
29. Agur, A., G. Amir, O. Paltiel, et al. 2014. CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. Leuk. Lymphoma 56:1315-1319. 2014 Oct [Epub ahead of print] doi: 10.3109/10428194.2014.963081
30. Weihrauch, M. R., O. Manzke, M. Beyer, et al. 2005. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in Primary Hodgkin's Disease: potential for a prognostic factor. Cancer Res. 65:5516-5519.
31. Niens, M., L. Visser, I. M. Nolte, et al. 2008. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br. J. Haematol. 140:527-536.
32. Sauer, M., A. Plütschow, R. D. Jachimowicz, et al. 2013. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am. J. Hematol. 88:113-115.
33. Plattel, W. J., A. Van den Berg, L. Visser, et al. 2012. Plasma thymus and activation-related chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica 97:410-415.
34. Jones, K., F. Vari, C. Keane, et al. 2013. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin. Cancer Res. 19:731-742.
35. Hasenclevear, D., and V. Diehl . 1998. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. 339: 1506-1514.
36. Noordijk, E. M., P. Carde, N. Dupouy, et al. 2006. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J. Clin. Oncol. 24:3128-3135.
37. Casasnovas, R. O., N. Mounier, P. Brice, et al. 2007. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 25:1732-1740.
38. Scott, D. W., F. C. Chan, F. Hon, et al. 2013. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J. Clin. Oncol. 31:692-700.